CXCL12 and hepatocellular carcinoma: Furthermore, the IHC results showed that during sorafenib treatment, CAFs reduced the sensitivity of HCC cells to sorafenib, while CXCL12 inhibition promoted the apoptosis of HCC cells (Fig. 5d-e).